SUPERNUS PHARMACEUTICALS, INC. (SUPN) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, SUPERNUS PHARMACEUTICALS, INC.'s filing signal turned negative.

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases. The company's diverse neuroscience portfolio includes approved treatments for ADHD, Parkinson's Disease complications, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Supernus leverages proprietary formulation technologies like Microtrol and Solutrol to enhance product efficacy and patient adherence. In July 2025, Supernus completed the acquisition of Sage Therapeutics, Inc., expanding its portfolio with ZURZUVAE for postpartum depression and strengthening its CNS pipeline. The company markets its products primarily in the U.S. through dedicated sales forces targeting specific medical specialties.

Revenue is primarily driven by net product sales of its commercialized CNS treatments in the U.S., supplemented by royalty and licensing revenues from collaboration agreements.